Evofem Biosciences, Inc. (EVFM)
- Previous Close
0.0154 - Open
0.0159 - Bid --
- Ask --
- Day's Range
0.0150 - 0.0159 - 52 Week Range
0.0120 - 3.7500 - Volume
157,974 - Avg. Volume
818,532 - Market Cap (intraday)
730,438 - Beta (5Y Monthly) -1.16
- PE Ratio (TTM)
0.32 - EPS (TTM)
0.0500 - Earnings Date Apr 26, 2024 - Apr 30, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women; and EVO200 for the prevention of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.
www.evofem.comRecent News: EVFM
Performance Overview: EVFM
Trailing total returns as of 4/22/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: EVFM
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: EVFM
Valuation Measures
Market Cap
730.44k
Enterprise Value
44.10M
Trailing P/E
0.32
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.86
Price/Book (mrq)
--
Enterprise Value/Revenue
2.42
Enterprise Value/EBITDA
-2.75
Financial Highlights
Profitability and Income Statement
Profit Margin
290.81%
Return on Assets (ttm)
-62.46%
Return on Equity (ttm)
--
Revenue (ttm)
18.22M
Net Income Avi to Common (ttm)
49.99M
Diluted EPS (ttm)
0.0500
Balance Sheet and Cash Flow
Total Cash (mrq)
--
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-7.15M